AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

Shares of AstraZeneca PLC AZN inched down 0.57% to £115.88 Monday, on what proved to be an all-around grim trading session ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

We recently compiled a list of 8 Cheap Growth Stocks to Buy According to Analysts. In this article, we will look at where ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...